Abstract
Clinical ThyroidologyVol. 29, No. 9 SummariesA Deiodinase 2 Polymorphism May Lower Serum T3 and Tissue T3 in Levothyroxine-Treated PatientsJerome M. HershmanJerome M. HershmanSearch for more papers by this authorPublished Online:1 Sep 2017https://doi.org/10.1089/ct.2017;29.338-340AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byThyroid Hormone Replacement – a Counterblast to Guidelines*1 December 2017 | Journal of the Royal College of Physicians of Edinburgh, Vol. 47, No. 4 Volume 29Issue 9Sep 2017 InformationCopyright 2017 American Thyroid Association, Inc.To cite this article:Jerome M. Hershman.A Deiodinase 2 Polymorphism May Lower Serum T3 and Tissue T3 in Levothyroxine-Treated Patients.Clinical Thyroidology.Sep 2017.338-340.http://doi.org/10.1089/ct.2017;29.338-340Published in Volume: 29 Issue 9: September 1, 2017PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
